Overview
A large observational study of nearly 1.4 million people in Japan found that cardiovascular-kidney-metabolic (CKM) syndrome is associated with increased cancer incidence, with risk rising as CKM stage worsens. Data were drawn from insurance claims and health checkups collected between April 2014 and August 2023, with a median follow-up just over three years. The authors stress the study is observational and cannot establish causation; statistically meaningful associations were limited to advanced stages.
Key findings
– Compared with lower or no CKM burden, cancer incidence increased by: stage 1: 3% higher; stage 2: 2% higher; stage 3: 25% higher; stage 4: 30% higher.
– Stages were defined by the number and severity of CKM components: cardiovascular disease, kidney disease, metabolic dysfunction, hypertension, excess adiposity, and abnormal blood sugar.
– Only the stage 3 and stage 4 increases were statistically robust after adjustment, supporting a stronger link at more advanced CKM.
Shared mechanisms and overlapping risk factors
The investigators and commentators pointed to biological and behavioral links that could explain the association: chronic systemic inflammation, insulin resistance, oxidative stress, and excess or dysfunctional adipose tissue. Common lifestyle and demographic risk factors such as aging, tobacco use, excess alcohol, poor diet, and physical inactivity contribute to both CKM progression and cancer risk.
Expert perspectives
Independent clinicians and researchers said the study adds to evidence connecting cardiometabolic and kidney disorders with cancer. Observers noted that the findings underscore prevention and early identification of at-risk patients rather than offering new, disease-specific cancer interventions. Inflammation was highlighted as a likely central driver, with obesity, insulin resistance, hypertension, and kidney dysfunction creating a cascade of cardiometabolic harm.
Context and prevalence
The American Heart Association introduced CKM syndrome as a concept in October 2023, recommending multidisciplinary prevention, screening, and management. A 2024 JAMA analysis estimated up to 90% of U.S. adults have at least some CKM components, with a reported distribution roughly: stage 0: 10%, stage 1: 26%, stage 2: 49%, stage 3: 5%, stage 4: 9%. Stage 1 typically reflects excess body fat and elevated blood sugar; stage 3 reflects subclinical cardiovascular abnormalities and high-risk chronic kidney disease; stage 4 includes established cardiovascular disease and, in some groups, kidney failure.
Prevention and clinical implications
The authors and independent experts recommend considering cancer risk in care plans for people with CKM, particularly those in advanced stages. Practical steps include:
– Ensure guideline-recommended cancer screening and consider earlier vigilance for patients with stage 3 or 4 CKM.
– Address shared risk factors through lifestyle change: healthier diet with fewer ultra-processed foods, regular physical activity, smoking cessation, and limiting alcohol.
– Optimize control of weight, blood pressure, blood glucose, and kidney function using guideline-directed therapies and multidisciplinary care when indicated.
Experts suggest starting with one or two achievable changes, such as increasing physical activity and reducing ultra-processed foods, and emphasize that therapies improving cardiovascular, metabolic, and kidney health may also lower cancer risk.
Limitations
The study is observational with a relatively short median follow-up of about three years. Those design features limit causal inference and long-term risk assessment. The stronger associations seen in later CKM stages are consistent with shared risk factors and advanced cardiometabolic disease driving much of the observed increase in cancer incidence.
Bottom line
CKM syndrome is common and, in this large observational cohort, linked to higher cancer risk that increases with disease stage—especially stage 3 and stage 4. The findings support integrating cancer prevention and screening into care for people with advanced CKM while reinforcing established strategies: improve diet, increase activity, avoid tobacco, limit alcohol, and manage cardiovascular, metabolic, and kidney risk factors.